Explore more Johnson & Johnson sites:
Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Clinical Trials
Please note that by clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Learn More
Please note that by clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Share
Health Workforce
very health worker trained and supported helps to build a stronger community, and every enhanced community brings the world one step closer toward achieving good health and well-being for all. A robust, trained and motivated healthcare workforce is critical to saving and improving the lives of women, children and their families while also improving national health outcomes. For decades, Johnson & Johnson has worked to strengthen the people at the front lines of delivering care. From getting young people interested in healthcare as a career, to supporting their clinical training as future front-line health workers and caregivers, we help to ensure they have the skills they need to improve and save lives.
Our Aspiration: A world where the current and future healthcare workforce has the necessary competencies to deliver high-quality healthcare.
5-Year Target: 650,000 health workers will have received training to better deliver quality healthcare.
Status: In Progress
Our Impact:
• Q&A: Putting Health Workers at the Center of Global Health Goals
• Training Ethnic Minority Midwives in Vietnam
• Project Hope: Indonesian Midwives Train in
Saving Lives at Birth
Related Content
Johnson & Johnson has signed up to the 2030 UN Sustainable Development Goals—the world’s road map for progress.
More From Johnson & Johnson
With its Phase 3 clinical trial now fully enrolled, the Global Head of Research & Development at Janssen brings us up to speed on the progress of the company's vaccine candidate, including upcoming key milestones.
The large-scale, pivotal, multi-country Phase 3 trial ( ENSEMBLE) of the investigational Janssen COVID-19 single-dose vaccine candidate is now fully enrolled with approximately 45,000 participants. Given the high incidence of COVID-19 among the general population in the countries where the trial is being conducted, this number of participants will be sufficient to generate the data needed to determine the efficacy and safety of the Company’s investigational COVID-19 vaccine candidate. Johnson & Johnson expresses its thanks to all participants, trial sites and health care professionals involved in the ENSEMBLE study.
With COVID-19 dominating the news this year, chances are you've also read about clinical studies that are underway for investigational vaccines. For a glimpse at what the experience of participating in a clinical study is like, we spoke to people across the country who took part in a clinical trial.
